177086-37-2

Basic information

• Product Name: 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE
• Synonyms: 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE;2'-Deoxy-5'-O-DMT-2'-fluorocytidine;5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-2'-fluoro-cytidine
• CAS NO: 177086-37-2
• Molecular Formula: C30H30FN3O6
• Molecular Weight: 547.57
• Mol File: 177086-37-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE(177086-37-2)
• EPA Substance Registry System: 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE(177086-37-2)

Safety Data

• Hazardous Substances Data: 177086-37-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE is used as a nucleoside building block for the synthetic preparation of di(2''-?deoxy-?2''-?fluoro)?nucleoside phosphates and phosphorothioates. These synthetic compounds have potential applications in the development of new drugs, particularly in the treatment of viral infections and cancer.
In the field of nucleic acid chemistry, this compound serves as an essential intermediate for the synthesis of modified oligonucleotides, which can be used as therapeutic agents or research tools for studying gene expression and regulation.
Additionally, 5'-O-(4,4'-DIMETHOXYTRITYL)-2'-FLUORO-D-CYTIDINE can be utilized in the development of novel drug delivery systems, such as nanoparticles or liposomes, to improve the bioavailability and targeting of therapeutic agents.

Upstream product

• 146954-76-9 N4-benzoyl-2-deoxy-2-fluorocytidine 

Relevant articles and documents

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

ANTISENSE MODULATION OF ENDOTHELIAL LIPASE EXPRESSION

Antisense compounds, compositions and methods are provided for modulating the expression of Endothelial Lipase (EL). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EL. Methods of using these compounds for modulation of EL expression and for treatment of diseases associated with expression of EL are provided.

Notch1 inhibitors for inducing apoptosis

Compounds, compositions and methods are provided for modulating the expression of Notch1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Notch1. Methods of using these compounds for modulation of Notch1 expression and for diagnosis and treatment of disease associated with expression Notch1 are provided.

Antisense modulation of PLML expression

Antisense compounds, compositions and methods are provided for modulating the expression of PLML. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PLML. Methods of using these compounds for modulation of PLML expression and for treatment of diseases associated with expression of PLML are provided.

OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS

Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.